Safety and Immunogenicity of NVX-CoV2705

计划入组 676 人 · 首次发布于 2025 年 7 月 23 日

Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years

计划入组 72 人 · 首次发布于 2026 年 8 月 27 日

Efficacy and Safety of NVX-CoV2705

计划入组 6,500 人 · 首次发布于 2025 年 7 月 25 日

SARS-CoV-2 vaccine

JN-001

JN-101

JN INTERNATIONAL MEDICAL CORPORATION

United States

NHI-1

United States

Xi'an No.1 Hospital

China

Pfizer and BioNTech's Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive CHMP Opinion

FDA Approves Updated COVID-19 Vaccines Targeting Omicron Subvariants for 2024-2025 Season

Pfizer and BioNTech Submit EMA Application for Updated COVID-19 Vaccine Targeting LP.8.1 Strain for 2025-2026 Season